Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia

[1] Yang H(2012)IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives Clin Cancer Res: Off J Am Assoc Cancer Res 18 5562-5571

[2] Ye D(2010)Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism JNCI J Natl Cancer Inst 102 932-941

[3] Guan K-L(2016)Targeting isocitrate dehydrogenase (IDH) in cancer Discov Med 21 373-380

[4] Xiong Y(2012)IDH mutation impairs histone demethylation and results in a block to cell differentiation Nature 483 474-478

[5] Reitman ZJ(2010)Cancer-associated IDH mutations: biomarker and therapeutic opportunities Oncogene 29 6409-6417

[6] Yan H(2010)IDH mutations in glioma and acute myeloid leukemia Trends Mol Med 16 387-397

[7] Fujii T(2009)Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 739-30

[8] Khawaja MR(2011)Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases Cancer Cell 19 17-567

[9] DiNardo CD(2010)Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation Cancer Cell 18 553-2498

[10] Atkins JT(2012)Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production Oncogene 31 2491-4652

[1] Yang H(2012)IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives Clin Cancer Res: Off J Am Assoc Cancer Res 18 5562-5571

[2] Ye D(2010)Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism JNCI J Natl Cancer Inst 102 932-941

[3] Guan K-L(2016)Targeting isocitrate dehydrogenase (IDH) in cancer Discov Med 21 373-380

[4] Xiong Y(2012)IDH mutation impairs histone demethylation and results in a block to cell differentiation Nature 483 474-478

[5] Reitman ZJ(2010)Cancer-associated IDH mutations: biomarker and therapeutic opportunities Oncogene 29 6409-6417

[6] Yan H(2010)IDH mutations in glioma and acute myeloid leukemia Trends Mol Med 16 387-397

[7] Fujii T(2009)Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 739-30

[8] Khawaja MR(2011)Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases Cancer Cell 19 17-567

[9] DiNardo CD(2010)Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation Cancer Cell 18 553-2498

[10] Atkins JT(2012)Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production Oncogene 31 2491-4652